DisruptIgnite

Description

Bloomlife brings pregnancy monitoring closer to home, reducing the need for frequent hospital visits. The company is developing proprietary technology to enable maternal and fetal heart rate monitoring and fetal non-stress testing (NST) at home. Alongside remote blood pressure and glucose tracking, these capabilities support more accessible care for high-risk pregnancies. Clinicians can review results remotely to guide care, making monitoring more convenient for expectant mothers.

Product

No items found.

Our Investment Thesis

Significant US Market Opportunity: Bloomlife addresses strong demand for more accessible pregnancy care in a sizable US market, where at-home fetal monitoring has yet to establish a clear market leader. Reimbursement-supported services create attractive economics for providers and the potential to reduce care delivery costs for payers. A strong team and support from leading obstetrics and gynaecology clinicians further strengthen Bloomlife’s ability to build clinical adoption and scale.
Proprietary Sensing Technology: Bloomlife’s proprietary fetal ECG sensing architecture combines an easy-to-use form factor with reliable signal acquisition to support maternal and fetal heart rate monitoring and lay the foundation for at-home NST. We see this technology as a key differentiator, with the potential to bring reliable clinical assessments into the home, subject to clearance for the expanded indication.
Comprehensive Platform: Bloomlife’s remote monitoring platform is designed to help clinicians and care teams assess maternal and fetal wellbeing remotely and make timely, informed care decisions. With at-home uterine activity monitoring and full NST indications progressing toward FDA clearance, the platform has the potential to extend clinical oversight beyond hospital walls.



CEO

Eric Dy

Location

San Francisco, USA

Website

Visit Site

Theme

#SelfCare

#SmartHospital